Centipede Venom Tops Morphine

The substance targets the same ion channel that's mutated in people who don't feel pain.

By | October 1, 2013

WIKIMEDIA, YASUNORI KOIDEAn alteration in a sodium ion channel can leave people completely indifferent to pain, making the channel an appealing target for analgesic development. In a report published in the Proceedings of the National Academy of Sciences this week (September 30), researchers characterize a newly discovered component of centipede venom that inhibits this particular sodium channel, NaV1.7, and works even better than morphine to dampen pain in rodents. “Centipedes worked out hundreds of millions of years ago the easiest way to catch prey was to paralyze them by blocking their NaV channel,” Glenn King, one of the authors of the study, told ABC. “We're just lucky that of the nine NaV channels in humans, it hit the one we were after.”

King, a researcher at the University of Queensland, said that other attempts to bind the NaV1.7 channel blocked other sodium channels and produced untoward effects. But King and his colleagues found that the venom-derived peptide was much more selective for 1.7 than for other sodium ion channels. And it showed no negative impacts on heart rate, blood pressure, or motor function. The centipede peptide was also more potent than morphine in a chemically induced pain assay in mice, and was just as effective as the narcotic in relieving pain induced by acid or heat.

Of course, a number of studies will have to validate the safety and efficacy of the drug before it could be used to treat pain in humans. Already, several venom-derived peptides have been developed for human therapy. King envisions that centipede venom could be useful in treating chronic pain. According to The Australian, it will be critical to “get the dose right” so that people could still feel a burn, for example. “But they wouldn’t have this ongoing pain, often resulting from a nerve injury or something that just hasn’t been dampened down by the brain,” King told The Australian.

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

  4. Another DNA Vaccine for Zika Shows Promise